---
title: "Analyst Reiterates Buy on Elanco After Strong Q1 Beat, Raised Guidance, and Attractive Valuation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285403073.md"
description: "William Blair analyst Brandon Vazquez has reiterated a Buy rating on Elanco (ELAN) following a strong Q1 performance that exceeded sales and EBITDA forecasts. He cites robust growth in the farm animal segment and an optimistic outlook for U.S. pet health growth as key factors. Management has raised full-year guidance, and Vazquez finds the current valuation attractive at about 20 times his 2027 EPS estimate. Bank of America Securities also maintains a Buy rating with a $30 price target."
datetime: "2026-05-06T15:15:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285403073.md)
  - [en](https://longbridge.com/en/news/285403073.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285403073.md)
---

# Analyst Reiterates Buy on Elanco After Strong Q1 Beat, Raised Guidance, and Attractive Valuation

William Blair analyst Brandon Vazquez has maintained their bullish stance on ELAN stock, giving a Buy rating on April 28.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Brandon Vazquez has given his Buy rating due to a combination of factors, including Elanco’s stronger-than-expected first-quarter performance, with both sales and EBITDA materially ahead of forecasts and robust organic growth in the farm animal segment. He also views the company’s outlook for accelerating U.S. pet health growth in the second half, supported by improving monthly trends, as a key catalyst for further stock appreciation.

In addition, Vazquez highlights survey work indicating that new products such as Befrena can capture meaningful share this year, supporting confidence in the company’s competitive position despite some debate around the longer-term trajectory of other brands. With management raising full-year guidance for revenue and organic growth and the shares trading at about 20 times his 2027 EPS estimate, he sees the current valuation as attractive relative to Elanco’s earnings potential and maintains his positive recommendation.

In another report released on April 28, Bank of America Securities also maintained a Buy rating on the stock with a $30.00 price target.

### Related Stocks

- [ELAN.US](https://longbridge.com/en/quote/ELAN.US.md)

## Related News & Research

- [Elanco Animal Health Q1 revenue and adjusted profit beats, lifts outlook](https://longbridge.com/en/news/285357239.md)
- [Assessing Elanco Animal Health (ELAN) Valuation After Advantage Collar Launch In Pet Health Market](https://longbridge.com/en/news/282613612.md)
- [SEAWORLD REACHES MILESTONE OF 43,000 ANIMAL RESCUES, UNDERSCORING THE ONGOING NEED TO HELP ANIMALS IN NEED | PRKS Stock News](https://longbridge.com/en/news/286771887.md)
- [03:15 ETCIGL, YOOV Deadline: CIGL, YOOV Investors Have Opportunity to Lead Concorde International Group Ltd. Securities Fraud Lawsuit](https://longbridge.com/en/news/287021785.md)
- [22:13 ETGLOB Investors Have Opportunity to Lead Globant S.A. Securities Fraud Lawsuit](https://longbridge.com/en/news/286842370.md)